布鲁顿酪氨酸激酶(BTK)抑制剂在治疗炎症免疫性疾病中的研究进展
Research progress of Bruton's tyrosine kinase(BTK)inhibitors in the treatment of inflammatory and immune-mediated diseases
任玮杰 1岑丽芳 1邹毅1
作者信息
- 1. 中国药科大学药学院, 南京 211198
- 折叠
摘要
布鲁顿酪氨酸激酶(Bruton's tyrosine kinase,BTK)是一种胞质酪氨酸激酶,参与B细胞和粒细胞的活化,在B细胞和Fcγ受体下游发挥作用.临床前研究表明,抑制BTK活性可能成为自身免疫性疾病和过敏等炎症免疫相关病症的潜在治疗方法.本文总结了BTK在免疫相关疾病中的作用机制,并对目前临床在研的BTK抑制剂用于免疫相关疾病治疗的研究情况进行了综述,以期为BTK抑制剂在非肿瘤适应证的研究提供新思路.
Abstract
Bruton's tyrosine kinase(BTK),a cytoplasmic tyrosine kinase,plays a central role in the activation of B cells and granulocytes,operating downstream of B cell and Fcγ receptors,and is considered an attractive target for treating autoimmune diseases.Preclinical investigations have demonstrated that inhibition of BTK activity holds promise as a potential therapeutic strategy for inflammatory immune responses such as autoimmune diseases and allergies.This review provides an overview of the mechanisms by which BTK contributes to immune-related diseases and summarizes current research on the development of BTK inhibitors for treating these conditions,aiming to offer novel insights into non-oncology applications for BTK inhibitors.
关键词
布鲁顿酪氨酸激酶/炎症免疫/自身免疫性疾病/过敏/临床研究Key words
BTK/inflammatory immunity/autoimmune diseases/allergy/clinical research引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据